Download presentation
Presentation is loading. Please wait.
Published byFranklin Jasper Young Modified over 5 years ago
1
Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia Yoshimitsu Soga, MD, Osamu Iida, MD, Keisuke Hirano, MD, Kenji Suzuki, MD, Daizo Kawasaki, MD, Yusuke Miyashita, MD, Taketsugu Tsuchiya, MD, Masakiyo Nobuyoshi, MD Journal of Vascular Surgery Volume 54, Issue 6, Pages (December 2011) DOI: /j.jvs Copyright © 2011 Society for Vascular Surgery Terms and Conditions
2
Fig 1 Kaplan-Meier curves show amputation-free survival rate in patients who did (+) and did not (–) receive cilostazol therapy. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2011 Society for Vascular Surgery Terms and Conditions
3
Fig 2 Kaplan-Meier curves show limb salvage rate in patients who did (+) and did not (–) receive cilostazol therapy. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2011 Society for Vascular Surgery Terms and Conditions
4
Fig 3 Kaplan-Meier curves show overall survival rate in patients who did (+) and did not (–) receive cilostazol therapy. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2011 Society for Vascular Surgery Terms and Conditions
5
Fig 4 Kaplan-Meier curves show freedom from cardiovascular death (CVD) in patients who did (+) and did not (–) receive cilostazol therapy. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2011 Society for Vascular Surgery Terms and Conditions
6
Fig 5 Kaplan-Meier curves show freedom from repeat revascularization in patients who did (+) and did not (–) receive cilostazol therapy. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2011 Society for Vascular Surgery Terms and Conditions
7
Fig 6 Univariate subgroup analysis shows amputation-free survival (AFS) in patients treated with cilostazol compared with those who did not receive cilostazol. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2011 Society for Vascular Surgery Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.